7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/17/2013

Company Name Symbol %Change
VIASAT INC VSAT
19.35%
OLD SECOND B OSBC
5.76%
GAMCO INVEST GBL
4.61%
CORNING GLW
4.47%
SYNCHRONOSS SNCR
4.23%

Pall Outpaces Estimates in 4Q

by Zacks Equity Research

September 13, 2012 | Comments : 0 Recommended this article: (0)
PLL

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Pall Corporation ( PLL - Analyst Report ) reported fourth-quarter fiscal 2012 earnings per share from continuing operations of 99 cents, up 28.6% from the Zacks Consensus Estimate of 77 cents. Reported earnings were also ahead of the prior-year level of 76 cents a share.

Revenue

Total revenue in the quarter inched up 0.4% year over year to $783.7 million, including a negative impact from foreign currency translation of 5 cents. Sales from continuing operation were $722.4 million, up 6.4% in local currency. Sales in the quarter were affected by weakness in Euro zone and ERP transition issues, which affected shipment of consumables.

Segment Revenue

Segment wise, the company’s revenue in the Life Sciences segment climbed 7.8% in local currency to $334 million while Industrial segment was up 5.2% in local currency to $387.7 million.

Within Life Sciences, Biopharmaceuticals sales were up 16.1%, Food & Beverage sales declined 9.1% while Medical sales grew 1.9% year over year in local currency. Within the Industrial segment, Process Technologies sales increased 3.8%, Aerospace sales surged 20.8% while sales of Microelectronics dipped 1.5%.

Margin

Gross margin in the quarter was 51.5% compared with 49.2% in the fourth quarter of fiscal 2011.

Life Sciences operating margin was 25.7% compared with 23.8% in the prior-year quarter. While Industrial segment operating margin was 17.4% versus 12.5% in the fourth quarter of 2011.

Balance Sheet and Cash Flow

Cash and cash equivalents were $500.2 million with long-term debt of $490.7 million and shareowner’s equity of $1,510.0 million.

Net cash flow from operations was $474.8 million compared with $430 million in the prior-year quarter.

Outlook

The weak macroeconomic condition, especially in Europe, is a matter of concern. Further, the company also expects slower global semiconductor end markets and moderating growth in some of the emerging markets. Based on this concern, the company reduced its lower end of the guidance. Earnings are now expected to be in the range of $5.05 to $5.25 for fiscal 2013.

Pall’s Aeropower business derives significant benefits from the emerging markets, particularly in Asia. Key drivers include increasing passenger air miles flown, ramp up in US military budgets, new military and commercial aircraft, and demand for new aircraft and mobile construction equipment. In the long run, Pall will likely benefit from several secular trends, such as global infrastructure growth, increasing demand for water filtration systems and continued steady growth in the medical and pharmaceutical markets.

However, change in product mix and product pricing may impact the company’s operating results, particularly with the expansion of the systems business. The company experiences significantly longer sales cycles in systems business with less predictable revenue and no certainty of future revenue streams from related consumable product offerings and services.

Pall currently has a Zacks #3 Rank, implying a short-term Hold rating on the stock.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.